67088-16-8

Upstream product

• 105485-45-8 3-C-benzyl-4-benzyloxy-2-hydroxyacetophenone 
• 3769-40-2 2-(phenylmethyl)-1,3-dihydroxybenzene 
• 75-05-8 acetonitrile 
• 29682-12-0 1-[4-(benzyloxy)-2-hydroxyphenyl]ethanone 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 151-10-0 1,3-Dimethoxybenzene 
• 32565-76-7 (2,6-dimethyloxy-4-methyl)phenyl 
• 118713-65-8 3-benzyl-2,4-dimethoxyacetophenone 

Downstream Products

• 95832-48-7 8-C-benzyl-7-acetoxy-3-acetyl-2-methyl-chromone 
• 105485-46-9 5-C-benzyl-2-hydroxy-3,4-dibenzyloxyacetophenone 
• 118683-04-8 4-(4-Acetyl-2-benzyl-3-hydroxy-phenoxymethyl)-3-methoxy-benzoic acid 
• 105485-53-8 5'-C-benzyl-2',3',4'-trihydroxydihydrochalcone 
• 105485-62-9 5'-C-benzyl-2'-hydroxy-3',4'-dimethoxydihydrochalcone 
• 105485-49-2 5'-C-benzyl-2'-hydroxy-3',4'-dibenzyloxychalcone 

Relevant academic research and scientific papers

THERAPEUTIC AGENT

A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of a chalcone compound, an acetophenone compound, a coumarin compound, a phthalide compound, derivatives thereof, and pharmacologically acceptable salts thereof.

Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes

Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group (e.g., the toluic acids 1

Aromatic Benzylation: Part V - Synthesis of Nuclear Benzylated Chalcones and Dihydrochalcones from Gallacetophenone and β-Resacetophenone as Analogues of Uvaretin and Isouvaretin

5-C-Benzylgallacetophenone (1b) has been prepared in two ways: (i) by treating gallacetophenone (1a) with benzyl alcohol in the presence of BF3-Et2O and (ii) by the Claisen rearrangement of 3,4-di-O-benzylgallacetophenone (1d) in TFA at room temperature.P

Aromatic Benzylation of 2,4-Dihydroxybenzoyl Derivatives and Synthesis of C-Benzylated Chromone, Isoflavone and Coumarin Derivatives

2,4-Dihydroxyacetophenone (1a) when reacted with benzyl alcohol in the presence of boron trifluoride etherate and dioxan affords a mixture of 5C-benzyl (2a; major component), 3C- (3a) and 3,5-di-C (4a) derivatives.The monobenzyl derivatives (2a and 3a) are also formed in similar proportions by keeping 2-hydroxy-4-benzyloxyacetophenone (5) with trifluoroacetic acid at room temperature for 70 hr.The above reactions when carried out on 2,4-dihydroxydesoxybenzoin (1c) and its 4-benzyl ether (6) yield the corresponding products (2c, 3c and 4c) in similar amounts.The Perkin reaction on C-benzylated acetophenones (2a, 3a and 4a) with Ac2O-NaOAc furnishes the corresponding 7-acetoxy-3-acetyl-C-benzyl-2-methylchromones (7a, 8a and 9a); whereas the same reaction on C-benzylated desoxybenzoins (2c, and 4c) gives 7-acetoxy-6C-benzyl-2-methylisoflavones (7b and 9b).Compound (2c) has also been converted into 6C-benzyl-4,7-dihydroxy-3-phenylcoumarin (11).